Related Experiment Video
Updated: Oct 19, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Advances in Lung Cancer Treatment]
1Klinik und Poliklinik für Innere Medizin II, Bereich Pneumologie, Klinikum der Universität Regensburg.
Immuno-Oncologic Monotherapy For Nsclc:
5-year survival data from the KEYNOTE-024 trial confirm the sustained efficacy of immuno-oncologic monotherapy in patients with NSCLC with high PD-L1 expression (≥ 50 %). DUAL IMMUNOTHERAPY IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE THERAPY FOR NSCLC: Nivolumab plus impilimumab in combination with 2 cycles of platinum-containing chemotherapy improves survival in NSCLC patients.
Novel Targets And Treatment Options:
Entrectinib and larotrectinib with efficacy in NTRK fusion-positive NSCLC. Selpercatinib and pralsetinib with efficacy in RET fusion-positive NSCLC. Mobocertinib with efficacy in EGFRex20ins mutation of the EGFR gene. Sotorasib with efficacy in kRAS-G12C mutation of NSCLC.
National Network Genomic Medicine Lung Cancer (Nngm):
The nationwide network nNGM provides NSCLC patients with access to state-of-the-art molecular diagnostics and the latest treatment options.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...